Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319314 · ClinicalTrials.gov registry record · Phase 1
GCC19CART for Patients With Metastatic Colorectal Cancer
A Phase 1 study of Colorectal Cancer, sponsored by Lyell Immunopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT05319314 is a Phase 1 study of Colorectal Cancer that is actively recruiting participants, run by Lyell Immunopharma. The registered enrollment target is 30 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05319314, a Phase 1 study of Colorectal Cancer, is actively recruiting participants, sponsored by Lyell Immunopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG GCC19CART
Study Locations (4)
California
- City of Hope Comprehensive Cancer Center - Duarte
- University of California San Francisco Medical Center - San Francisco
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2032-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05319314
The ClinicalTrials.gov registry entry for NCT05319314 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Lyell Immunopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which GCC19CART is the first listed.
NCT05319314 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05319314 about?
NCT05319314 is a clinical study titled "GCC19CART for Patients With Metastatic Colorectal Cancer". Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
What is the current status of trial NCT05319314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-08-01. Estimated completion is 2032-06.
What conditions does trial NCT05319314 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05319314?
The interventions under investigation include: GCC19CART (DRUG).
Who is sponsoring clinical trial NCT05319314?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05319314 being conducted?
This trial has 4 study locations across California, Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.